Prostate cancer- a biomarker perspective

Frontiers in Endocrinology

Volumn 3, Issue MAY, 2012, Pages

  Liu, Yanqiu ^a   Hegde, Priti ^b   Zhang, Fengmin ^c   Hampton, Garret ^b   Jia, Shidong ^b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Personalized medicine; Prostate cancer

Indexed keywords

EID: 84872847620     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00072     Document Type: Article

References (51)

1. Aihara, M., Lebovitz, R. M., Wheeler, T. M., Kinner, B. M., Ohori, M., and Scardino, P. T. (1994). Prostate specific antigen and glea-son grade: an immunohistochemical study of prostate cancer. J. Urol. 151, 1558-1564.
2. Amler, L. C., Agus, D. B., Leduc, C., Sapinoso, M. L., Fox, W. D., Kern, S., Lee, D., Wang, V., Ley-sens, M., Higgins, B., Martin, J., Gerald, W., Dracopoli, N., Cordon-Cardo, C., Scher, H. I., and Hampton, G. M. (2000). Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 60, 6134-6141.
3. Andriole, G. L., Bostwick, D. G., Braw-ley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., Somerville, M. C., Wilson, T. H., Fowler, I. L., and Rittmaster, R. S. (2010). Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202.
4. Armstrong, A. J., Eisenberger, M. A., Halabi, S., Oudard, S., Nanus, D. M., Petrylak, D. P., Sartor, A. O., and Scher, H. I. (2011). Biomark-ers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol. 61, 549-559.
5. Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H., Vickers, E., A'hern, R., Levink, R., Coumans, F., Mor-eira, J., Riisnaes, R., Oommen, N. B., Hawche, G., Jameson, C., Thompson, E., Sipkema, R., Carden, C. P., Parker, C., Dearnaley, D., Kaye, S. B.,Cooper, C. S., Molina, A., Cox, M. E., Terstappen, L. W., and de Bono, J. S. (2009). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912-2918.
6. Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
7. Bryant, R. J., Pawlowski, T., Catto, J. W., Marsden, G., Vessella, R. L., Rhees, B., Kuslich, C., Visakorpi, T., and Hamdy, F. C. (2012). Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106, 768-774.
8. Clegg, N. J., Couto, S. S., Wongvipat, J., Hieronymus, H., Carver, B. S., Taylor, B. S., Ellwood-Yen, K., Gerald, W. L., Sander, C., and Sawyers, C. L. (2011). MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE 6, e17449. doi: 10.1371/journal. pone.0017449
9. Danila, D. C., Pantel, K., Fleisher, M., and Scher, H. I. (2011). Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J. 17, 438-450.
10. Darson, M. F., Pacelli, A., Roche, P., Rittenhouse, H. G., Wolfert, R. L., Young, C. Y., Klee, G. G., Tindall, D. J., and Bostwick, D. G. (1997). Human glandular kallikrein 2 (hK2) expression in prostatic intraepithe-lial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49, 857-862.
11. de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstap-pen, L. W., Pienta, K. J., and Ragha-van, D. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309.
12. Ding, Z., Wu, C. J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., Hoshida, Y., Hiller, D., Hu, B., Jiang, S., Zheng, H., Stegh, A. H., Scott, K. L., Sig-noretti, S., Bardeesy, N., Wang, Y. A., Hill, D. E., Golub, T. R., Stampfer, M. J., Wong, W. H., Loda, M., Mucci, L., Chin, L., and Depinho, R. A. (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273.
13. Ding, Z., Wu, C. J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Pro-topopov, A., Chu, G. C., Wang, G., Lu, X., Labrot, E. S., Hu, J., Wang, W., Xiao, Y., Zhang, H., Zhang, J., Gan, B., Perry, S. R., Jiang, S., Li, L., Horner, J. W., Wang, Y. A., Chin, L., and Depinho, R. A. (2012). Telom-erase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148, 896-907.
14. Duijvesz, D., Luider, T., Bangma, C. H., and Jenster, G. (2011). Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 59, 823-831.
15. Gulley, J. L., and Drake, C. G. (2011). Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17, 3884-3891.
16. Gutman, A. B., and Gutman, E. B. (1938). An "Acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J. Clin. Invest. 17, 473-478.
17. Hegde, P. S., Rusnak, D., Bertiaux, M., Alligood, K., Strum, J., Gagnon, R., and Gilmer, T. M. (2007). Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol. Cancer Ther. 6, 1629-1640.
18. Henrique, R., and Jeronimo, C. (2004). Molecular detection of prostate cancer: a role for GSTP1 hyperme-thylation. Eur. Urol. 46, 660-669; discussion 669.
19. Hricak, H., Choyke, P. L., Eberhardt, S. C., Leibel, S. A., and Scardino, P. T. (2007). Imaging prostate cancer: a multidisciplinary perspective. Radiology 243, 28-53.
20. Hu, R., Denmeade, S. R., and Luo, J. (2010). Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev. Endocrinol. Metab. 5, 753-764.
21. Ilic, N., Utermark, T., Widlund, H. R., and Roberts, T. M. (2011). PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. U.S.A. 108, E699-E708.
22. Jadvar, H. (2009). FDG PET in prostate cancer. PET Clin. 4, 155-161.
23. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., and Zhao, J. J. (2008). Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776-779.
24. Jia, S., Roberts, T. M., and Zhao, J. J. (2009). Should individual PI3 kinase isoforms be targeted in cancer? Curr. Opin. Cell Biol. 21, 199-208.
25. Kobayashi, Y., Absher, D. M., Gulzar, Z. G., Young, S. R., Mckenney, J. K., Peehl, D. M., Brooks, J. D., Myers, R. M., and Sherlock, G. (2011). DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 21, 1017-1027.
26. Lackner, M. R. (2010). Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Rev. Mol. Diagn. 10, 75-87.
27. Lin, D. W., Fitzgerald, L. M., Fu, R., Kwon, E. M., Zheng, S. L., Kolb, S., Wiklund, F., Stattin, P., Isaacs, W. B., Xu, J., Ostrander, E. A., Feng, Z., Gronberg, H., and Stanford, J. L. (2011). Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol. Biomarkers Prev. 20, 1928-1936.
28. Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., Gray, N. S., Mona-han, J., Schlegel, R., Beroukhim, R., Mills, G. B., and Zhao, J. J. (2011). Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 17, 1116-1120.
29. Madu, C. O., and Lu, Y. (2010). Novel diagnostic biomarkers for prostate cancer. J. Cancer 1, 150-177.
30. Makarov, D. V., Loeb, S., Getzen-berg, R. H., and Partin, A. W. (2009). Biomarkers for prostate cancer. Annu. Rev. Med. 60, 139-151.
31. Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'briant, K. C., Allen, A., Lin, D. W., Urban, N., Drescher, C. W., Knudsen, B. S., Stirewalt, D. L., Gentleman, R., Vessella, R. L., Nelson, P. S., Martin, D. B., and Tewari, M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105, 10513-10518.
32. Nakajima, T., Mitsunaga, M., Bander, N. H., Heston, W. D., Choyke, P. L., and Kobayashi, H. (2011). Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug. Chem. 22, 1700-1705.
33. Pinto, F., Totaro, A., Palermo, G., Calarco, A., Sacco, E., D'addessi, A., Racioppi, M., Valentini, A., Gui, B., and Bassi, P. (2012). Imaging in prostate cancer staging: present role and future perspectives. Urol. Int. 88, 125-136.
34. Punnoose, E. A., Atwal, S. K., Spo-erke, J. M., Savage, H., Pandita, A., Yeh, R. F., Pirzkall, A., Fine, B. M., Amler, L. C., Chen, D. S., and Lackner, M. R. (2010). Molecular biomarker analyses using circulating tumor cells. PLoS ONE 5, e12517. doi: 10.1371/journal.pone.0012517
35. Roberts, M. J., Schirra, H. J., Lavin, M. F., and Gardiner, R. A. (2011). Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J. Urol. 52, 79-89.
36. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29.
37. Spratlin, J. L., Serkova, N. J., and Eck-hardt, S. G. (2009). Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440.
38. Sreekumar, A., Poisson, L. M., Rajendi-ran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C., and Chin-naiyan, A. M. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
39. Sun, Y., Wang, B. E., Leong, K. G., Yue, P., Li, L., Jhunjhunwala, S., Chen, D., Seo, K., Modrusan, Z., Gao, W. Q., Settleman, J., and Johnson, L. (2012). Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 72, 527-536.
40. Tavazoie, S. F., Alarcon, C., Oskars-son, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., and Mas-sague, J. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152.
41. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N., Landers, T., Dolgalev, I., Major, J. E., Wilson, M., Socci, N. D., Lash, A. E., Heguy, A., Eastham, J. A., Scher, H. I., Reuter, V. E., Scardino, P. T., Sander, C., Sawyers, C. L., and Gerald, W. L. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
42. Taylor, D. D., and Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13-21.
43. Tessem, M. B., Swanson, M. G., Keshari, K. R., Albers, M. J., Joun, D., Tabatabai, Z. L., Simko, J. P., Shino-hara, K., Nelson, S. J., Vigneron, D. B., Gribbestad, I. S., and Kurhanewicz, J. (2008). Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 60, 510-516.
44. Thompson, I. M., Goodman, P. J., Tan-gen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., and Coltman, C. A. Jr. (2003). The influence of finas-teride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224.
45. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., and Coltman, C. A. Jr. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N. Engl. J. Med. 350, 2239-2246.
46. Tomlins, S. A., Aubin, S. M., Siddiqui, J., Lonigro, R. J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., Penabella, Y., Day, J. R., Varambally, R., Han, B., Wood, D., Wang, L., Sanda, M. G., Rubin, M. A., Rhodes, D. R., Hollenbeck, B., Sakamoto, K., Silber-stein, J. L., Fradet, Y., Amberson, J. B., Meyers, S., Palanisamy, N., Rit-tenhouse, H., Wei, J. T., Groskopf, J., and Chinnaiyan, A. M. (2011). Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3, 94ra72.
47. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., and Lotvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654-659.
48. Walsh, P. C. (2010). Chemoprevention of prostate cancer. N. Engl. J. Med. 362, 1237-1238.
49. Yap, T. A., Zivi, A., Omlin, A., and de Bono, J. S. (2011). The changing therapeutic landscape of castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 8, 597-610.
50. Zafarana, G., Ishkanian, A. S., Malloff, C. A., Locke, J. A., Sykes, J., Thoms, J., Lam, W. L., Squire, J. A., Yoshimoto, M., Ramnarine, V. R., Meng, A., Ahmed, O., Jurisca, I., Milosevic, M., Pintilie, M., Van Der Kwast, T., and Bristow, R. G. (2012). Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer. doi: 10.1002/cncr.26729 [Epub ahead of print].
51. Zhang, H. L., Yang, L. F., Zhu, Y., Yao, X. D., Zhang, S. L., Dai, B., Zhu, Y. P., Shen, Y. J., Shi, G. H., and Ye, D. W. (2011). Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential pre-dictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71, 326-331.